The Selimetry trial has now closed. There is a new trial underway for patients whose thyroid cancer is no longer responsive the RAI treatment. Your oncologist will have to ensure that you fit into the criteria necessary for the trial. You can be referred to any of the following centres . Bristol Haematology and Oncology […]Read More >>
The IoN trial is the only national clinical study of thyroid cancer in the UK. Funded by Cancer Research UK, it aims to show whether certain patients with well-differentiated thyroid cancer need radioiodine ablation or not, when they have already had their thyroid gland removed and are on hormone treatment. The clinicians have been searching […]Read More >>
The latest UK Thyroid Cancer Clinical Trial ION is well underway with more than 110 patients who are already taking part in this important study of thyroid cancer. The UK HiLo study results were reported in the top medical journal, theNew England Journal of Medicine, in May 2012. It showed that selected patients with well-differentiated […]Read More >>
An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease 10 countries, 34 sites plus seven back-up sites Hopefully five UK centres – Cardiff, Christie, Royal Marsden, Barts and Newcastle – will […]Read More >>
Allan Hackshaw, Deputy Director of Cancer Research UK, comments: “Recommended treatment for most patients with differentiated thyroid cancer is surgery followed by a high administered dose of 3.7 GBq (100mCi) radioiodine ablation. However, a lower dose (1.1 GBq or 30 mCi) has advantages including a shorter stay in hospital isolation and lower risk of side […]Read More >>
We are available on this number on Tuesdays and Fridays from 10 am to 4 pm. Outside these times, please leave a message on our answer phone and we will get back to you as soon as we can.